IN2014CN02050A - - Google Patents

Info

Publication number
IN2014CN02050A
IN2014CN02050A IN2050CHN2014A IN2014CN02050A IN 2014CN02050 A IN2014CN02050 A IN 2014CN02050A IN 2050CHN2014 A IN2050CHN2014 A IN 2050CHN2014A IN 2014CN02050 A IN2014CN02050 A IN 2014CN02050A
Authority
IN
India
Prior art keywords
wehvnaiqearrll
seq
acid sequence
relates
present
Prior art date
Application number
Other languages
English (en)
Inventor
Anthony Cerami
Michael Brines
Thomas Coleman
Original Assignee
Araim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araim Pharmaceuticals Inc filed Critical Araim Pharmaceuticals Inc
Publication of IN2014CN02050A publication Critical patent/IN2014CN02050A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
IN2050CHN2014 2005-08-05 2006-08-07 IN2014CN02050A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70574105P 2005-08-05 2005-08-05
US70627605P 2005-08-08 2005-08-08
US83173706P 2006-07-18 2006-07-18
PCT/US2006/031061 WO2007019545A2 (en) 2005-08-05 2006-08-07 Tissue protective peptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2014CN02050A true IN2014CN02050A (es) 2015-05-29

Family

ID=37728020

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2050CHN2014 IN2014CN02050A (es) 2005-08-05 2006-08-07

Country Status (26)

Country Link
US (7) US8071554B2 (es)
EP (5) EP2540309B1 (es)
JP (6) JP5274253B2 (es)
KR (7) KR20170027868A (es)
CN (2) CN103724418B (es)
AU (1) AU2006278264B2 (es)
BR (1) BRPI0614529A8 (es)
CA (3) CA3079319A1 (es)
DK (3) DK2540309T3 (es)
EA (1) EA015672B1 (es)
ES (3) ES2653790T3 (es)
HK (1) HK1127751A1 (es)
HU (3) HUE035655T2 (es)
IL (3) IL189287A (es)
IN (1) IN2014CN02050A (es)
LT (2) LT2594279T (es)
MX (3) MX2008001509A (es)
NO (1) NO20081112L (es)
NZ (1) NZ565937A (es)
PL (3) PL2540309T3 (es)
PT (3) PT2371855E (es)
SG (2) SG10201805825SA (es)
SI (3) SI2540309T1 (es)
UA (1) UA100222C2 (es)
WO (1) WO2007019545A2 (es)
ZA (1) ZA201101890B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) * 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
KR20170027868A (ko) 2005-08-05 2017-03-10 아라임 파마슈티칼즈, 인크. 조직 보호 펩티드 및 이의 용도
EP2047859A4 (en) * 2006-06-07 2010-05-05 Univ Tokushima TREATMENT OF ISCHEMIC DISEASE USING ERYTHROPOIETIN
DK2081956T3 (da) * 2006-11-13 2013-06-24 Charite Universitaetsmedizin FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT
AU2014203195B2 (en) * 2008-01-22 2016-03-31 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
SG188161A1 (en) * 2008-01-22 2013-03-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2016203452B2 (en) * 2008-01-22 2018-02-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9566349B2 (en) * 2010-10-14 2017-02-14 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
US8791234B2 (en) * 2010-10-14 2014-07-29 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
CN102180948A (zh) * 2011-03-03 2011-09-14 复旦大学附属中山医院 一种具有肾脏保护作用的短肽及其制备方法和应用
CN102212111B (zh) * 2011-05-05 2014-04-30 中国人民解放军第三军医大学 小分子多肽和小分子多肽脂质体及其运用
CA2843014C (en) * 2011-07-27 2020-01-21 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
WO2013042118A1 (en) * 2011-09-20 2013-03-28 A.A. Cash Technology Ltd Methods and devices for occluding blood flow to an organ
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
WO2013158871A1 (en) * 2012-04-20 2013-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of erythropoietin and derivatives for treating hypertension
JP6479789B2 (ja) * 2013-07-17 2019-03-13 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
CN104744593A (zh) * 2013-12-25 2015-07-01 深圳先进技术研究院 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR20150130616A (ko) * 2014-05-13 2015-11-24 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
CN105906690A (zh) * 2014-06-22 2016-08-31 马恒标 组织保护活性多肽sl9及其应用
JP7011830B2 (ja) 2015-10-14 2022-01-27 エックス－サーマ インコーポレイテッド 氷晶形成を低減するための組成物および方法
CN109310741A (zh) 2016-04-29 2019-02-05 阿拉伊姆药品公司 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽
CN110234311B (zh) 2016-11-10 2022-08-12 Asc瑞珍尼特有限公司 含有促红细胞生成素衍生的分子的用于局部应用的美容制剂
CN110475786A (zh) * 2017-02-27 2019-11-19 大邱庆北科学技术院 红细胞生成素衍生肽通过其对预防细胞损伤的作用的用途
US11260101B2 (en) 2017-02-28 2022-03-01 Jinan University Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
KR20200142521A (ko) * 2018-04-08 2020-12-22 브림 바이오테크놀로지, 인코퍼레이티드 Pedf-유래 짧은 펩타이드의 힘줄 치유에의 적용
KR102300060B1 (ko) 2018-06-12 2021-09-08 주식회사 엘지에너지솔루션 2열 터미널 구조의 pcb 다이렉트 커넥터
EP3849605A4 (en) 2018-09-10 2022-06-15 Cold Spring Harbor Laboratory METHODS OF TREATMENT OF PANCREATITIS
CN112390877B (zh) * 2019-08-16 2022-10-04 董红燕 Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5498694A (en) 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6063625A (en) * 1993-02-12 2000-05-16 Board Of Trustees Of Leland S, Stanford, Jr. University Regulated transcription of targeted genes and other biological events
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
EP1510524A3 (en) * 1995-06-07 2006-06-07 Ortho Pharmaceutical Corporation Compounds and peptides that bind to the erythropoietin receptor
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
JP2003520194A (ja) * 1999-04-13 2003-07-02 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド 末梢投与したエリスロポエチンによる興奮組織機能のモジュレート
WO2001083548A1 (fr) * 2000-04-28 2001-11-08 Effector Cell Institute Nouveau derive de facteur chimiotactique cellulaire
MXPA03005406A (es) * 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PL362396A1 (en) * 2001-02-06 2004-11-02 Merck Patent Gmbh Modified erythropoietin (epo) with reduced immunogenicity
JP2005503127A (ja) * 2001-04-04 2005-02-03 ジェンオディセ エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
AU2003251770B9 (en) 2002-07-01 2009-06-04 H. Lundbeck A/S Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
KR100478455B1 (ko) 2002-08-19 2005-03-22 삼성전자주식회사 전자렌지
ZA200505423B (en) 2002-09-09 2008-08-27 Warren Pharmaceuticals Inc Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
EP1578432A4 (en) * 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
JP2004305006A (ja) * 2003-04-01 2004-11-04 Japan Science & Technology Agency 人工調製肺サーファクタント
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
CN103230415B (zh) * 2003-04-25 2016-05-04 匹兹堡大学联邦制高等教育 用于促进和增强神经修复和再生的肌肉来源的细胞（mdc）
CN1882355A (zh) 2003-09-09 2006-12-20 沃伦药品公司 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
CN1897959A (zh) 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
KR20170027868A (ko) 2005-08-05 2017-03-10 아라임 파마슈티칼즈, 인크. 조직 보호 펩티드 및 이의 용도
PT2492355E (pt) 2007-11-29 2015-09-10 Molecular Health Gmbh Recetor de eritropoietina protetora de tecido (nepor) e métodos de utilização
SG188161A1 (en) 2008-01-22 2013-03-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2009243187C1 (en) * 2008-04-28 2015-12-24 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2011022056A2 (en) 2009-08-18 2011-02-24 Medical College Of Georgia Research Institute, Inc. PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF

Also Published As

Publication number Publication date
CN101378772B (zh) 2013-12-04
IL189287A0 (en) 2008-06-05
CA2982909A1 (en) 2007-02-15
SI2371855T1 (sl) 2015-11-30
DK2540309T3 (en) 2018-01-08
SI2594279T1 (en) 2018-04-30
ZA201101890B (en) 2012-12-27
ES2653790T3 (es) 2018-02-08
HUE035793T2 (en) 2018-05-28
EP1924276A4 (en) 2009-07-22
KR20200072568A (ko) 2020-06-22
EP2594279A1 (en) 2013-05-22
CA2618396A1 (en) 2007-02-15
CN101378772A (zh) 2009-03-04
ES2550055T3 (es) 2015-11-04
EA015672B1 (ru) 2011-10-31
SI2540309T1 (en) 2018-04-30
CA3079319A1 (en) 2007-02-15
WO2007019545A2 (en) 2007-02-15
EP2540309B1 (en) 2017-11-22
HUE035655T2 (en) 2018-05-28
IL239695A0 (en) 2015-08-31
MX2008001509A (es) 2008-04-04
LT2540309T (lt) 2018-01-10
SG10201805825SA (en) 2018-08-30
JP5274253B2 (ja) 2013-08-28
JP2013126995A (ja) 2013-06-27
NZ565937A (en) 2011-09-30
NO20081112L (no) 2008-05-05
JP2020078317A (ja) 2020-05-28
BRPI0614529A8 (pt) 2016-07-12
CN103724418A (zh) 2014-04-16
EP2371855B1 (en) 2015-07-22
KR101713368B1 (ko) 2017-03-07
JP2016196480A (ja) 2016-11-24
JP6491621B2 (ja) 2019-03-27
KR20190084136A (ko) 2019-07-15
EA200800536A1 (ru) 2009-02-27
PL2540309T3 (pl) 2018-03-30
IL189287A (en) 2015-07-30
MX339613B (es) 2016-06-02
PT2371855E (pt) 2015-11-03
US20190016769A1 (en) 2019-01-17
US20120142595A1 (en) 2012-06-07
AU2006278264A1 (en) 2007-02-15
US20140323401A1 (en) 2014-10-30
US20150152156A1 (en) 2015-06-04
DK2371855T3 (en) 2015-09-21
US8071554B2 (en) 2011-12-06
UA100222C2 (uk) 2012-12-10
KR20130080481A (ko) 2013-07-12
US8673861B2 (en) 2014-03-18
JP2009508471A (ja) 2009-03-05
US20160244498A1 (en) 2016-08-25
JP2015134772A (ja) 2015-07-27
WO2007019545A3 (en) 2008-10-02
US8716245B2 (en) 2014-05-06
EP2594279B1 (en) 2017-11-22
US10100096B2 (en) 2018-10-16
EP1924276A2 (en) 2008-05-28
CA2618396C (en) 2018-02-27
MX364100B (es) 2019-04-12
KR101626153B1 (ko) 2016-06-01
PT2594279T (pt) 2017-12-29
EP2540309A3 (en) 2013-05-29
KR20180067735A (ko) 2018-06-20
DK2594279T3 (en) 2018-01-08
IL261346A (en) 2018-10-31
KR20170027868A (ko) 2017-03-10
HUE026444T2 (en) 2016-05-30
US20090221482A1 (en) 2009-09-03
JP2018134084A (ja) 2018-08-30
LT2594279T (lt) 2018-01-10
JP6158235B2 (ja) 2017-07-05
EP2540309A2 (en) 2013-01-02
ES2653864T3 (es) 2018-02-09
EP3363451A1 (en) 2018-08-22
KR20180116475A (ko) 2018-10-24
HK1127751A1 (en) 2009-10-09
EP2371855A1 (en) 2011-10-05
AU2006278264B2 (en) 2012-12-06
PT2540309T (pt) 2017-12-29
BRPI0614529A2 (pt) 2011-08-09
PL2371855T3 (pl) 2015-12-31
CN103724418B (zh) 2018-03-06
JP5918155B2 (ja) 2016-05-18
SG2014007868A (en) 2014-05-29
PL2594279T3 (pl) 2018-03-30
US20120264682A1 (en) 2012-10-18
KR20080064800A (ko) 2008-07-09
US9340598B2 (en) 2016-05-17

Similar Documents

Publication Publication Date Title
IN2014CN02050A (es)
EP1801206A4 (en) PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE
NZ600690A (en) Fkbp-l and uses thereof
MX2008009493A (es) Peptido novedoso y uso del mismo.
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
MX2010004371A (es) Proteasa de streptomyces.
NZ602170A (en) Modified leptin polypeptides and their uses
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2008113536A8 (en) Neurotrophic peptides
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2010057242A3 (de) Vakzin
WO2007058267A8 (ja) 新規タンパク質及びそれをコードする遺伝子
DE50213015D1 (de) Lipase-varianten
WO2007066018A3 (fr) Peptides qui peuvent se lier a la proteine nef et leurs applications pharmaceutiques
MY150639A (en) T cell adhesion molecule and antibody thereto
CY1111630T1 (el) Παραγωγα κυτοκινων
WO2004096832A3 (en) Novel antiangiogenic peptides
WO2006123157A3 (en) Nematistatic protein
WO2011061720A3 (en) Viral citrullinated peptides and uses thereof
AU2007258875A8 (en) Recombinant novirhabdoviruses and uses thereof
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
NZ593086A (en) Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility
CA2530731A1 (en) Peptide having apoptosis-inhibiting activity